Mark M Pomerantz
Overview
Explore the profile of Mark M Pomerantz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2668
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamaguchi T, Houlahan K, Zhu H, Kurganovs N, Livingstone J, Fox N, et al.
Cancer Discov
. 2025 Feb;
PMID: 39945744
Newly diagnosed prostate cancers differ dramatically in mutational composition and lethality. The most accurate clinical predictor of lethality is tumor tissue architecture, quantified as tumor grade. To interrogate the evolutionary...
2.
Stopsack K, Vijai J, Conry M, Berchuck J, Kemel Y, Vasselman S, et al.
Clin Cancer Res
. 2024 Oct;
31(1):122-129.
PMID: 39450704
Purpose: Deleterious germline variants in certain DNA repair genes are risk factors for developing aggressive prostate cancer. The objective was to quantify their prognostic impact after prostate cancer diagnosis. Experimental...
3.
Choudhury A, Kwak L, Cheung A, Allaire K, Marquez J, Yang D, et al.
Cancer Immunol Res
. 2024 Mar;
12(6):704-718.
PMID: 38552171
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P)...
4.
Stone B, Labban M, Beatrici E, Filipas D, Frego N, Qian Z, et al.
World J Urol
. 2024 Jan;
42(1):54.
PMID: 38244128
Purpose: To evaluate how limited English proficiency (LEP) impacts the prevalence of prostate-specific antigen (PSA) screening in a contemporary, nationally representative cohort of men in the USA. Methods: The Medical...
5.
Chen N, McGrath C, Ericsson C, Vaselkiv J, Rencsok E, Stopsack K, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Jan;
33(3):419-425.
PMID: 38189661
Background: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced...
6.
McKay R, Xie W, Yang X, Acosta A, Rathkopf D, Laudone V, et al.
Cancer
. 2024 Jan;
130(9):1629-1641.
PMID: 38161319
Background: Patients with localized, unfavorable intermediate-risk and high-risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 of this phase...
7.
Rencsok E, Slopen N, Mcmanus H, Autio K, Morgans A, McSwain L, et al.
Cancer Res Commun
. 2023 Dec;
4(1):55-64.
PMID: 38108490
Significance: Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population...
8.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Dec;
30(3):907.
PMID: 38049623
No abstract available.
9.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Oct;
29(11):2737-2741.
PMID: 37865722
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and...
10.
Rana H, Stopfer J, Weitz M, Kipnis L, Koeller D, Culver S, et al.
JCO Oncol Pract
. 2023 Sep;
19(11):1069-1079.
PMID: 37733980
Purpose: Germline genetic testing (GT) is recommended for men with prostate cancer (PC), but testing through traditional models is limited. The ProGen study examined a novel model aimed at providing...